SARS-CoV-2 Nucleic Acid Detection Kit (PCR-Fluorescent Probe Method)
May 10, 2021 Zybio News
-
April 21, 2025
DiagHub Online Academic Platform: The First Session on Clinical Chemistry Concludes Successfully
-
April 16, 2025
Higher Accuracy While ~40% Time Saved: Reliable Dispersion Method of Zybio MALDI-TOF MS Platform Boosting Identification Rates
-
April 16, 2025
~94% Accuracy While Shortening TAT to 5 Minutes: Explore Zybio MALDI-TOF MS with Advanced Rapid Blood Culture Enrichment Technology
On April 1st, SARS-CoV-2 Nucleic Acid Detection Kit (PCR-Fluorescent Probe Method) developed by Zybio obtained the medical device registration certificate of CFDA.
According to the Work Manual of Nucleic Acid Testing for SARS-CoV-2 in Medical Institutions released by Joint Prevention and Control Mechanism of the State Council on December 28th, 2020, it is recommended to use reagents with high sensitivity (LoD ≤500 copies/ml) and above the double target area for detection, and use the matching VTM and extraction kits recommended in the IFU.
Primers and probes for SARS-CoV-2 nucleic acid detection
Furthermore, As early as March 9th, 2020, Zybio has obtained the CE certification of SARS-CoV-2 Nucleic Acid Detection Kit, providing VTM, automatic nucleic acid isolation system EXM3000, EXM6000, and nucleic acid extraction and detection kit for nearly 100 countries including ASEAN countries. Zybio's molecular products will continue to fight against the global COVID-19 pandemic and protect human health.